You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

Claims for Patent: 10,383,961

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,383,961

Title:	PET tracer for imaging of neuroendocrine tumors
Abstract:	There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Inventor(s):	Kjaer; Andreas (Frederiksberg, DK), Knigge; Ulrich (Kobenhavn O, DK), Hojgaard; Liselotte (Kobenhavn O, DK), Rasmussen; Palle (Roskilde, DK)
Assignee:	SOMSCAN APS (Frederiksberg, DK)
Application Number:	16/179,453
Patent Claims:	1. A method for imaging a neuroendocrine tumor in a human patient, the method comprising: a) administering to a human patient an imaging composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof: ##STR00003## b) conducting a radiographic imaging method on the patient after administration of the imaging composition; and c) making a radiographic image of the patient for detecting the compound of Formula I; wherein the radiographic image is diagnostic for the presence of a neuroendocrine tumor in the patient. 2. The method of claim 1, wherein the imaging composition further comprises a scavenger. 3. The method of claim 2, wherein the scavenger is gentisic acid. 4. The method of claim 1, wherein the imaging composition further comprises sodium acetate. 5. The method of claim 1, wherein the tumor is a neuroendocrine tumor metastasis. 6. The method of claim 1, wherein the radiographic imaging method is performed 1 hour after administration of the imaging composition. 7. The method of claim 1, wherein the radiographic imaging method is performed 3 hours after administration of the imaging composition. 8. The method of claim 1, wherein the radiographic imaging method is performed 24 hours after administration of the imaging composition. 9. The method of claim 1, wherein the radiographic imaging method is selected from the group consisting of planar imaging, positron emission tomography (PET), computed tomography (CT), single photon computed tomography (SPECT), and combinations thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.